[ad_1]
Israel’s largest healthcare provider, Clalit Health Services, on Sunday provided data showing a 94% drop in symptomatic COVID-19 infections in people who received two doses of the Pfizer and BioNTech vaccine.
On top of that, Clalit’s study showed that the same group of people vaccinated were 92% less likely to contract serious illnesses from COVID-19.
This brand is the largest “real world” study of vaccine performance: 1.2 million vaccinated and unvaccinated participants participated in the study. Half of the participants received the Pfizer vaccine, the other half did not.
“This unequivocally shows that Pfizer’s coronavirus vaccine is extremely effective in the real world one week after the second dose, just as it was found in the clinical study, ”said Ran Balicer, chief innovation officer of Clalit.
What the clinical study found
Not only does the vaccine have a high success rate, the Jerusalem Post reported that it has also found it to be just as effective for people aged 70 and over as it is for young people. In the study, some 170,000 vaccinated participants were over 60 years of age.
Mirroring Pfizer’s own clinical studies, Clalit’s study found the vaccine to be most effective one week after receiving the second dose. And as a start of further results, the vaccine was found to potentially have an even higher rate for the prevention of symptomatic and severe disease after 14 or more days of vaccination.
The two groups of participants were matched on level of risk of catching COVID-19, age, health, etc., Clalit explained. The healthcare provider is expected to release full results in the coming weeks.
As Reuters points out, Israel has acted swiftly by rolling out the COVID-19 vaccine to its residents, offering a database with information on the vaccine’s effectiveness and when countries might expect immunity. collective comes into force.
[ad_2]
Source link